<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39416971</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2575-9108</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>ACS pharmacology &amp; translational science</Title><ISOAbbreviation>ACS Pharmacol Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Evaluation of Angiotensin-Converting Enzyme 2 Expression <i>In Vivo</i> with Novel <sup>68</sup>Ga-Labeled Peptides Originated from the Coronavirus Receptor-Binding Domain.</ArticleTitle><Pagination><StartPage>3119</StartPage><EndPage>3130</EndPage><MedlinePgn>3119-3130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsptsci.4c00316</ELocationID><Abstract><AbstractText>Angiotensin-converting enzyme 2 (ACE2) is not only a key to the renin-angiotensin-aldosterone system and related diseases, but also the main entry point on cell surfaces for certain coronaviruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2. By analyzing the different key binding sites from the receptor-binding domain (RBD) of SARS-CoV and SARS-CoV-2, nine new ACE2-targeting peptides (A<b>1</b> to A<b>9</b>) were designed, synthesized and connected with a chelator, 1,4,7-triazacyclononane-<i>N,N',N'</i>'-triacetic acid (NOTA). NOTA-A<b>1</b>, NOTA-A<b>2</b>, NOTA-A<b>4</b>, NOTA-A<b>5</b>, and NOTA-A<b>8</b> were successfully labeled with [<sup>68</sup>Ga]Ga<sup>3+</sup> and were used for biological evaluation. [<sup>68</sup>Ga]Ga-NOTA-A<b>2</b>, [<sup>68</sup>Ga]Ga-NOTA-A<b>5</b>, and [<sup>68</sup>Ga]Ga-NOTA-A<b>8</b> showed specific binding to ACE2 via cell assays, and their binding sites and binding capacity were calculated by molecular docking and molecular dynamics simulations. In tumor-bearing mice, A549 tumors were visualized 60 min postinjection of [<sup>68</sup>Ga]Ga-NOTA-A<b>2</b>, [<sup>68</sup>Ga]Ga-NOTA-A<b>5</b>, or [<sup>68</sup>Ga]Ga-NOTA-A<b>8</b>. These peptides also accumulated in the organs with high-level ACE2 expression, confirmed by immunohistochemical stain. Among them, [<sup>68</sup>Ga]Ga-NOTA-A<b>5</b> exhibited the highest tumor uptake and tumor/background ratio, and it successfully tracked the increased ACE2 levels in mice tissues after excessive Losartan treatment. In a first-in-human study, the distribution of [<sup>68</sup>Ga]Ga-NOTA-A<b>5</b> was evaluated with positron emission tomography/computed tomography (PET/CT) in three participants without adverse events. <sup>68</sup>Ga-labeled peptides originated from the coronavirus RBD, with [<sup>68</sup>Ga]Ga-NOTA-A<b>5</b> as a typical representative, seem to be safe and effective for the evaluation of ACE2 expression <i>in vivo</i> with PET/CT, facilitating further mechanism investigation and clinical evaluation of ACE2-related diseases.</AbstractText><CopyrightInformation>© 2024 American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Rongxi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Theoretical and Computational Photochemistry, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Theoretical and Computational Photochemistry, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guochang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiarou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ziying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory of Theoretical and Computational Photochemistry, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xingtong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eight-Year Program of Clinical Medicine, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eight-Year Program of Clinical Medicine, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Huimin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Lianghui</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4414-3671</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Theoretical and Computational Photochemistry, Ministry of Education, College of Chemistry, Beijing Normal University, Beijing 100875, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Zhaohui</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0008-7394-9889</Identifier><AffiliationInfo><Affiliation>Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Pharmacol Transl Sci</MedlineTA><NlmUniqueID>101721411</NlmUniqueID><ISSNLinking>2575-9108</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare the following competing financial interest(s): L. L., G. H., Z. J. and Z. Z hold the patent rights for [68Ga]Ga-NOTA-A2/5/8 and related technology. Other authors declare no other conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>5</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39416971</ArticleId><ArticleId IdType="pmc">PMC11475584</ArticleId><ArticleId IdType="doi">10.1021/acsptsci.4c00316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hatmal M. M. M.; Alshaer W.; Al-Hatamleh M. A. I.; Hatmal M.; Smadi O.; Taha M. O.; Oweida A. J.; Boer J. C.; Mohamud R.; Plebanski M. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells 2020, 9 (12), 2638.10.3390/cells9122638.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122638</ArticleId><ArticleId IdType="pmc">PMC7763676</ArticleId><ArticleId IdType="pubmed">33302501</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J.; Ye G.; Shi K.; Wan Y.; Luo C.; Aihara H.; Geng Q.; Auerbach A.; Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature 2020, 581 (7807), 221–224. 10.1038/s41586-020-2179-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2179-y</ArticleId><ArticleId IdType="pmc">PMC7328981</ArticleId><ArticleId IdType="pubmed">32225175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.; Zhang Y.; Wu L.; Niu S.; Song C.; Zhang Z.; Lu G.; Qiao C.; Hu Y.; Yuen K. Y.; Wang Q.; Zhou H.; Yan J.; Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020, 181 (4), 894–904 e9. 10.1016/j.cell.2020.03.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.045</ArticleId><ArticleId IdType="pmc">PMC7144619</ArticleId><ArticleId IdType="pubmed">32275855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.; Wang R.; Wang M.; Wei G.-W. Mutations Strengthened SARS-CoV-2 Infectivity. J. Mol. Biol. 2020, 432 (19), 5212–5226. 10.1016/j.jmb.2020.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2020.07.009</ArticleId><ArticleId IdType="pmc">PMC7375973</ArticleId><ArticleId IdType="pubmed">32710986</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur V.; Ratho R. K. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J. Med. Virol. 2022, 94 (5), 1821–1824. 10.1002/jmv.27541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27541</ArticleId><ArticleId IdType="pubmed">34936120</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.; Waris H.; Rafique M.; Suleman M.; Mohammad A.; Ali S. S.; Khan T.; Waheed Y.; Liao C.; Wei D.-Q. The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. Int. J. Biol. Macromol. 2022, 200, 438–448. 10.1016/j.ijbiomac.2022.01.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.01.059</ArticleId><ArticleId IdType="pmc">PMC8767976</ArticleId><ArticleId IdType="pubmed">35063482</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawad B.; Adhikari P.; Podgornik R.; Ching W.-Y. Binding Interactions between Receptor-Binding Domain of Spike Protein and Human Angiotensin Converting Enzyme-2 in Omicron Variant. J. Phys. Chem. Lett. 2022, 13 (17), 3915–3921. 10.1021/acs.jpclett.2c00423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.2c00423</ArticleId><ArticleId IdType="pmc">PMC9063111</ArticleId><ArticleId IdType="pubmed">35481766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hikmet F.; Mear L.; Edvinsson A.; Micke P.; Uhlen M.; Lindskog C. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 2020, 16 (7), e961010.15252/msb.20209610.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20209610</ArticleId><ArticleId IdType="pmc">PMC7383091</ArticleId><ArticleId IdType="pubmed">32715618</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg M.; Maralakunte M.; Garg S.; Dhooria S.; Sehgal I.; Bhalla A. S.; Vijayvergiya R.; Grover S.; Bhatia V.; Jagia P.; Bhalla A.; Suri V.; Goyal M.; Agarwal R.; Puri G. D.; Sandhu M. S. The Conundrum of’Long-COVID-19’: A Narrative Review. Int. J. Gen Med. 2021, 14, 2491–2506. 10.2147/IJGM.S316708.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S316708</ArticleId><ArticleId IdType="pmc">PMC8214209</ArticleId><ArticleId IdType="pubmed">34163217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M.; Chen S.; Huang B.; Zhong J. M.; Su H.; Chen Y. J.; Cao Q.; Ma L.; He J.; Li X. F.; Li X.; Zhou J. J.; Fan J.; Luo D. J.; Chang X. N.; Arkun K.; Zhou M.; Nie X. Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications. Eur. Urol Focus 2020, 6 (5), 1124–1129. 10.1016/j.euf.2020.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2020.05.009</ArticleId><ArticleId IdType="pmc">PMC7261470</ArticleId><ArticleId IdType="pubmed">32563676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf U. M.; Abokor A. A.; Edwards J. M.; Waigi E. W.; Royfman R. S.; Hasan S. A.-M.; Smedlund K. B.; Hardy A. M. G.; Chakravarti R.; Koch L. G. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol. Genomics 2021, 53, 51–60. 10.1152/physiolgenomics.00087.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00087.2020</ArticleId><ArticleId IdType="pmc">PMC7900915</ArticleId><ArticleId IdType="pubmed">33275540</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B.; Singh D.; Verma V.; Yadav R.; Kumar R. Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19: A review. J. Pharm. Anal. 2022, 12 (2), 215–220. 10.1016/j.jpha.2021.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpha.2021.12.003</ArticleId><ArticleId IdType="pmc">PMC8677424</ArticleId><ArticleId IdType="pubmed">34934510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z.; Orchard S. G.; Nelson M. R.; Fravel M. A.; Ernst M. E. Angiotensin Receptor Blockers and Cognition: a Scoping Review. Curr. Hypertens. Rep. 2024, 26 (1), 1–19. 10.1007/s11906-023-01266-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-023-01266-0</ArticleId><ArticleId IdType="pmc">PMC10796582</ArticleId><ArticleId IdType="pubmed">37733162</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen H.; Zhang J.; Wang C.; Jain P. P.; Xiong M.; Shi X.; Lei Y.; Chen S.; Yin Q.; Thistlethwaite P. A.; Wang J.; Gong K.; Yuan Z.-Y.; Yuan J. X. J.; Shyy J. Y. J. MDM2-Mediated Ubiquitination of Angiotensin-Converting Enzyme 2 Contributes to the Development of Pulmonary Arterial Hypertension. Circulation 2020, 142 (12), 1190–1204. 10.1161/CIRCULATIONAHA.120.048191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048191</ArticleId><ArticleId IdType="pmc">PMC7497891</ArticleId><ArticleId IdType="pubmed">32755395</ArticleId></ArticleIdList></Reference><Reference><Citation>Memon B.; Abdelalim E. M. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. Acta Physiol. 2021, 233 (4), e1373310.1111/apha.13733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13733</ArticleId><ArticleId IdType="pmc">PMC8646749</ArticleId><ArticleId IdType="pubmed">34561952</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai P.; Yu J.; Ge S.; Jia R.; Fan X. Genetic alteration,RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J. Hematol. Oncol. 2020, 13 (1), 43.10.1186/s13045-020-00883-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00883-5</ArticleId><ArticleId IdType="pmc">PMC7197362</ArticleId><ArticleId IdType="pubmed">32366279</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.; Zhao R.; Hong H.; Li G.; Zhang Y.; Luo Y.; Zha Z.; Zhu J.; Qiao J.; Zhu L.; Kung H. F. 68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic beta-cell and insulinoma. Nucl. Med. Biol. 2021, 102–103, 87–96. 10.1016/j.nucmedbio.2021.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nucmedbio.2021.10.001</ArticleId><ArticleId IdType="pubmed">34695640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W.; Rosenkrans Z. T.; Liu J.; Huang G.; Luo Q.-Y.; Cai W. ImmunoPET: Concept, Design, and Applications. Chem. Rev. 2020, 120 (8), 3787–3851. 10.1021/acs.chemrev.9b00738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00738</ArticleId><ArticleId IdType="pmc">PMC7265988</ArticleId><ArticleId IdType="pubmed">32202104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.; Chen Y.; Hou Y. N.; Liu Q.; Zhang D.; Zhao H.; Zhang Y.; An S.; Li L.; Hou J.; Huang G.; Liu J.; Zhao Y. J.; Wei W. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur. J. Nucl. Med. Mol. Imaging 2021, 48 (9), 2749–2760. 10.1007/s00259-021-05218-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05218-1</ArticleId><ArticleId IdType="pubmed">33543326</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D.; Ding J.; Liu T. L.; Wang F.; Meng X. X.; Liu S.; Yang Z.; Zhu H. SARS-CoV-2 receptor binding domain radio-probe: a non-invasive approach for angiotensin-converting enzyme 2 mapping in mice. Acta Pharmacol. Sin 2022, 43 (7), 1749–1757. 10.1038/s41401-021-00809-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00809-y</ArticleId><ArticleId IdType="pmc">PMC8609177</ArticleId><ArticleId IdType="pubmed">34815544</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian J.; Huang H.; Huang G.; Zhou R.; Yang M.; Qiu Y.; Bi L.; Su Z.; Xiao F.; Shan H.; Jin H. A Positron Emission Tomography Tracer Targeting the S2 Subunit of SARS-CoV-2 in Extrapulmonary Infections. Mol. Pharm. 2022, 19 (11), 4264–4274. 10.1021/acs.molpharmaceut.2c00584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.2c00584</ArticleId><ArticleId IdType="pubmed">36067000</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L.; Sexton D. J.; Skogerson K.; Devlin M.; Smith R.; Sanyal I.; Parry T.; Kent R.; Enright J.; Wu Q. L.; Conley G.; DeOliveira D.; Morganelli L.; Ducar M.; Wescott C. R.; Ladner R. C. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 2003, 278 (18), 15532–15540. 10.1074/jbc.M212934200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M212934200</ArticleId><ArticleId IdType="pubmed">12606557</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker M. F. L.; Blecha J.; Rosenberg O.; Ohliger M.; Flavell R. R.; Wilson D. M. Cyclic 68Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2. J. Nucl. Med. 2021, 62 (11), 1631–1637. 10.2967/jnumed.120.261768.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.120.261768</ArticleId><ArticleId IdType="pmc">PMC8612341</ArticleId><ArticleId IdType="pubmed">33637588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.; Liu T.; Ding J.; Zhou N.; Yu Z.; Ren Y.; Qin X.; Du P.; Yang Z.; Zhu H. Evaluation of 68Ga- and 177Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging. Mol. Pharma. 2022, 19 (11), 4149–4156. 10.1021/acs.molpharmaceut.2c00541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.2c00541</ArticleId><ArticleId IdType="pubmed">36198565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H.; Zhang H.; Zhou N.; Ding J.; Jiang J.; Liu T.; Liu Z.; Wang F.; Zhang Q.; Zhang Z.; Yan S.; Li L.; Benabdallah N.; Jin H.; Liu Z.; Cai L.; Thorek D. L. J.; Yang X.; Yang Z. Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2. Adv. Sci. 2021, 8 (16), e210096510.1002/advs.202100965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202100965</ArticleId><ArticleId IdType="pmc">PMC8373167</ArticleId><ArticleId IdType="pubmed">34174177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren F.; Jiang H.; Shi L.; Zhang L.; Li X.; Lu Q.; Li Q. 68Ga-cyc-DX600 PET/CT in ACE2-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 2023, 50, 2056–2067. 10.1007/s00259-023-06159-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-023-06159-7</ArticleId><ArticleId IdType="pmc">PMC9969023</ArticleId><ArticleId IdType="pubmed">36847824</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.; Yin W.; Li A.; Li D.; Gao X.; Wang R.; Cui B.; Qiu S.; Li R.; Jia L.; Zuo C.; Zhang L.; Li M. ACE2 PET to reveal the dynamic patterns of ACE2 recovery in an infection model with pseudocorona virus. J. Med. Virol. 2023, 95 (2), e2847010.1002/jmv.28470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28470</ArticleId><ArticleId IdType="pubmed">36606602</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer D.; Vaccarin C.; Deupi X.; Mapanao A. K.; Cohrs S.; Sozzi-Guo F.; Grundler P. V.; van der Meulen N. P.; Wang J.; Tanriver M.; Bode J. W.; Schibli R.; Muller C. A tool for nuclear imaging of the SARS-CoV-2 entry receptor: molecular model and preclinical development of ACE2-selective radiopeptides. EJNMMI Res. 2023, 13 (1), 32.10.1186/s13550-023-00979-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13550-023-00979-2</ArticleId><ArticleId IdType="pmc">PMC10113987</ArticleId><ArticleId IdType="pubmed">37074529</ArticleId></ArticleIdList></Reference><Reference><Citation>Struck A. W.; Axmann M.; Pfefferle S.; Drosten C.; Meyer B. A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antiviral Res. 2012, 94 (3), 288–296. 10.1016/j.antiviral.2011.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2011.12.012</ArticleId><ArticleId IdType="pmc">PMC7114193</ArticleId><ArticleId IdType="pubmed">22265858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J.; Ge J.; Yu J.; Shan S.; Zhou H.; Fan S.; Zhang Q.; Shi X.; Wang Q.; Zhang L.; Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020, 581, 215–220. 10.1038/s41586-020-2180-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong R.; Wang F.; Zhang J.; Wang F. F.; Chang S. CoDockPP: A Multistage Approach for Global and Site-Specific Protein-Protein Docking. J. Chem. Inf. Model. 2019, 59 (8), 3556–3564. 10.1021/acs.jcim.9b00445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.9b00445</ArticleId><ArticleId IdType="pubmed">31276391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong R.; Liu R. R.; Xu X. M.; Zhang D. W.; Xu X. S.; Shi H.; Chang S. Template-based modeling and ab-initio docking using CoDock in CAPRI. Proteins 2020, 88 (8), 1100–1109. 10.1002/prot.25892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25892</ArticleId><ArticleId IdType="pubmed">32181952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lensink M. F.; Brysbaert G.; Nadzirin N.; Velankar S.; Chaleil R. A. G.; Gerguri T.; Bates P. A.; Laine E.; Carbone A.; Grudinin S.; Kong R.; Liu R. R.; Xu X. M.; Shi H.; Chang S.; Eisenstein M.; Karczynska A.; Czaplewski C.; Lubecka E.; Lipska A.; Krupa P.; Mozolewska M.; Golon Ł.; Samsonov S.; Liwo A.; Crivelli S.; Pagès G.; Karasikov M.; Kadukova M.; Yan Y.; Huang S. Y.; Rosell M.; Rodríguez-Lumbreras L. A.; Romero-Durana M.; Díaz-Bueno L.; Fernandez-Recio J.; Christoffer C.; Terashi G.; Shin W. H.; Aderinwale T.; Maddhuri Venkata Subraman S. R.; Kihara D.; Kozakov D.; Vajda S.; Porter K.; Padhorny D.; Desta I.; Beglov D.; Ignatov M.; Kotelnikov S.; Moal I. H.; Ritchie D. W.; Chauvot de Beauchêne I.; Maigret B.; Devignes M. D.; Ruiz Echartea M. E.; Barradas-Bautista D.; Cao Z.; Cavallo L.; Oliva R.; Cao Y.; Shen Y.; Baek M.; Park T.; Woo H.; Seok C.; Braitbard M.; Bitton L.; Scheidman-Duhovny D.; Dapk̅nas J.; Olechnovič K.; Venclovas Č.; Kundrotas P. J.; Belkin S.; Chakravarty D.; Badal V. D.; Vakser I. A.; Vreven T.; Vangaveti S.; Borrman T.; Weng Z.; Guest J. D.; Gowthaman R.; Pierce B. G.; Xu X.; Duan R.; Qiu L.; Hou J.; Ryan Merideth B.; Ma Z.; Cheng J.; Zou X.; Koukos P. I.; Roel-Touris J.; Ambrosetti F.; Geng C.; Schaarschmidt J.; Trellet M. E.; Melquiond A. S. J.; Xue L.; Jiménez-García B.; van Noort C. W.; Honorato R. V.; Bonvin A. M. J. J.; Wodak S. J. Blind prediction of homo- and hetero-protein complexes: The CASP13-CAPRI experiment. Proteins 2019, 87 (12), 1200–1221. 10.1002/prot.25838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25838</ArticleId><ArticleId IdType="pmc">PMC7274794</ArticleId><ArticleId IdType="pubmed">31612567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q.; Peng Z.; Zhang Y.; Yang J. COACH-D: improved protein–ligand binding sites prediction with refined ligand-binding poses through molecular docking. Nucleic Acids Res. 2018, 46 (W1), W438–W442. 10.1093/nar/gky439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky439</ArticleId><ArticleId IdType="pmc">PMC6030866</ArticleId><ArticleId IdType="pubmed">29846643</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P.; Jin B.; Li H.; Huang S.-Y. HPEPDOCK: a web server for blind peptide–protein docking based on a hierarchical algorithm. Nucleic Acids Res. 2018, 46 (W1), W443–W450. 10.1093/nar/gky357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky357</ArticleId><ArticleId IdType="pmc">PMC6030929</ArticleId><ArticleId IdType="pubmed">29746661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace A. C.; Laskowski R.; Thornton J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127–134. 10.1093/protein/8.2.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/8.2.127</ArticleId><ArticleId IdType="pubmed">7630882</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshar-Oromieh A.; Hetzheim H.; Kübler W.; Kratochwil C.; Giesel F. L.; Hope T. A.; Eder M.; Eisenhut M.; Kopka K.; Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1611–1620. 10.1007/s00259-016-3419-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-016-3419-0</ArticleId><ArticleId IdType="pubmed">27260521</ArticleId></ArticleIdList></Reference><Reference><Citation>Delker A.; Schleske M.; Liubchenko G.; Berg I.; Zacherl M. J.; Brendel M.; Gildehaus F. J.; Rumiantcev M.; Resch S.; Hürkamp K.; Wenter V.; Unterrainer L. M.; Bartenstein P.; Ziegler S. I.; Beyer L.; Böning G. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&amp;T/[225Ac]Ac-PSMA-I&amp;T therapy using multi-isotope quantitative SPECT imaging. Eur. J. Nucl. Med. Mol. Imaging 2023, 50 (5), 1280–1290. 10.1007/s00259-022-06092-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-06092-1</ArticleId><ArticleId IdType="pmc">PMC10027798</ArticleId><ArticleId IdType="pubmed">36629878</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z.; Topol E. Solving the puzzle of Long Covid. Science 2024, 383 (6685), 830–832. 10.1126/science.adl0867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adl0867</ArticleId><ArticleId IdType="pubmed">38386747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.; Bu X.; Fang G.; Luan G.; Huang Y.; Akdis C. A.; Wang C.; Zhang L. Distinct expression of SARS-CoV-2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps. Allergy 2021, 76 (3), 789–803. 10.1111/all.14665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14665</ArticleId><ArticleId IdType="pmc">PMC7753806</ArticleId><ArticleId IdType="pubmed">33210729</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimoura H.; Tanaka H.; Matsumoto K.; Mochizuki Y.; Hatani Y.; Hatazawa K.; Matsuzoe H.; Ooka J.; Sano H.; Sawa T.; Motoji Y.; Ryo-Koriyama K.; Hirata K. i. Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients. Heart Vessels 2017, 32, 584–590. 10.1007/s00380-016-0904-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00380-016-0904-0</ArticleId><ArticleId IdType="pubmed">27722772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G. H. J.; Melgoza A.; Jiang F.; Guo S. The efect of renin-angiotensin-aldosterone system inhibitors on organ-specifc ACE2 expression in zebrafsh and its implications for COVID-19. Sci. Rep. 2021, 11, 23670.10.1038/s41598-021-03244-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-03244-5</ArticleId><ArticleId IdType="pmc">PMC8655050</ArticleId><ArticleId IdType="pubmed">34880395</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuhashi M.; Moniwa N.; Mita T.; Fuseya T.; Ishimura S.; Ohno K.; Shibata S.; Tanaka M.; Watanabe Y.; Akasaka H.; Ohnishi H.; Yoshida H.; Takizawa H.; Saitoh S.; Ura N.; Shimamoto K.; Miura T. Urinary ACE2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker. Am. J. Hypertens 2015, 28 (1), 15–21. 10.1093/ajh/hpu086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajh/hpu086</ArticleId><ArticleId IdType="pubmed">24842388</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M.; Vardeny O.; Michel T.; McMurray J. J. V.; Pfeffer M. A.; Solomon S. D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19 N. Engl. J. Med. 2020, 382, 1653–1659. 10.1056/NEJMsr2005760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr2005760</ArticleId><ArticleId IdType="pmc">PMC7121452</ArticleId><ArticleId IdType="pubmed">32227760</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla A. K.; Banerjee M. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update. High Blood Press Car. 2021, 28 (2), 129–139. 10.1007/s40292-021-00439-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40292-021-00439-9</ArticleId><ArticleId IdType="pmc">PMC7908946</ArticleId><ArticleId IdType="pubmed">33635533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer A.; Schreinlechner M.; Sappler N.; Dolejsi T.; Tilg H.; Aulinger B. A.; Weiss G.; Bellmann-Weiler R.; Adolf C.; Wolf D.; Pirklbauer M.; Graziadei I.; Gänzer H.; Bary C. V.; May A. E.; Wöll E.; Scheidt W. V.; Rassaf T.; Duerschmied D.; Brenner C.; Kääb S.; Metzler B.; Joannidis M.; Kain H.-U.; Kaiser N.; Schwinger R.; Witzenbichler B.; Alber H.; Straube F.; Hartmann N.; Achenbach S.; Bergwelt-Baildon M. V.; Stülpnagel L. V.; Schoenherr S.; Forer L.; Embacher-Aichhorn S.; Mansmann U.; Rizas K. D.; Massberg S. Discontinuation versus continuation of renin-angiotensinsystem inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir. Med. 2021, 9, 863–872. 10.1016/S2213-2600(21)00214-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00214-9</ArticleId><ArticleId IdType="pmc">PMC8195495</ArticleId><ArticleId IdType="pubmed">34126053</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. H.; Hao Q. Q.; Wang X. Y.; Chen X.; Wang N.; Zhu L.; Li S. Y.; Yu Q. T.; Dong B. ACE2 activity was increased in atherosclerotic plaque by losartan: Possible relation to anti-atherosclerosis. J. Renin-Angio-Aldo Syst. 2015, 16 (2), 292–300. 10.1177/1470320314542829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1470320314542829</ArticleId><ArticleId IdType="pubmed">25070352</ArticleId></ArticleIdList></Reference><Reference><Citation>Poormoosavi S. M.; Behmanesh M. A.; Abeyat H.; Sangtarash E. Evaluation of the Effect of Captopril and Losartan on Tacrolimus-induced Nephrotoxicity in Rats. Drug Res. 2021, 71 (5), 243–249. 10.1055/a-1369-8651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1369-8651</ArticleId><ArticleId IdType="pubmed">33711846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal S.; Chen Y.; Lockbaum G. J.; Sen S.; Chaudhuri S.; Reyes A. C.; Lee J. M.; Kaur A. N.; Sultana N.; Cameron M. D.; Shaffer S. A.; Schiffer C. A.; Fitzgerald K. A.; Thompson P. R. Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2. J. Am. Chem. Soc. 2022, 144 (46), 21035–21045. 10.1021/jacs.2c04626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c04626</ArticleId><ArticleId IdType="pmc">PMC9662648</ArticleId><ArticleId IdType="pubmed">36356199</ArticleId></ArticleIdList></Reference><Reference><Citation>Best R. B.; Zhu X.; Shim J.; Lopes P. E. M.; Mittal J.; Feig M.; MacKerell A. D. Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone ϕ, ψ and Side-Chain χ1 and χ2 Dihedral Angles. J. Chem. Theory Comput. 2012, 8 (9), 3257–3273. 10.1021/ct300400x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct300400x</ArticleId><ArticleId IdType="pmc">PMC3549273</ArticleId><ArticleId IdType="pubmed">23341755</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Spoel D.; Lindahl E.; Hess B.; Groenhof G.; Mark A. E.; Berendsen H. J. C. GROMACS: Fast, flexible, and free. J. Comput. Chem. 2005, 26 (16), 1701–1718. 10.1002/jcc.20291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20291</ArticleId><ArticleId IdType="pubmed">16211538</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangone A.; Schaarschmidt J.; Koukos P.; Geng C.; Citro N.; Trellet M. E.; Xue L. C.; Bonvin A. M. J. J.; Valencia A.; Valencia A. Large-scale prediction of binding affinity in protein–small ligand complexes: the PRODIGY-LIG web server. Bioinformatics 2019, 35 (9), 1585–1587. 10.1093/bioinformatics/bty816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty816</ArticleId><ArticleId IdType="pubmed">31051038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>